Skip to main content
. 2021 Sep 11;398(10304):981–990. doi: 10.1016/S0140-6736(21)01699-8

Figure 5.

Figure 5

Antibody responses in participants who received a third dose of ChAdOx1 nCoV-19

(A) Antibody levels to SARS-CoV-2 Victoria/01/2020 spike protein measured by total IgG ELISA (n=75). Datapoints in lighter colours represent individual participants and darker datapoints show median values with error bars showing the IQRs and with solid lines connecting these median values. (B) Neutralisation titres from a randomly selected subset of participants (45 of 75 participants who received a third dose of vaccine and who had an interval of 8–16 weeks between their first and second dose). Datapoints represent individual participants for the three variants of concern investigated. FRNT50=focus reduction neutralisation titres with 50% neutralisation cutoff.